If you've been following 3SBio lately, you know the stock has been nothing short of a rollercoaster ride, with all the excitement and nerves that come with it. Maybe you're holding on for the long term, or maybe you're itching to make a move. Either way, it's worth taking a closer look at where things stand, especially with valuation in mind.
Here's what's hard to ignore: over the last year, 3SBio's share price has surged an eye-popping 420.4%, with year-to-date returns of 404.2%. Even the three- and five-year numbers are strong at 478.0% and 277.9%, respectively. That's not to say things have always gone smoothly. The past week brought a slide of -3.5%, and the 30-day result is a modest 0.6% uptick. Still, these figures hint at a company that's captured fresh attention, possibly as investors rethink the sector in light of new market dynamics, or as confidence grows in the company's fundamentals and growth potential.
With all this action, the big question is whether the current price still offers any real value. That's where things get interesting: on our valuation scorecard, 3SBio checks in at 4 out of 6, indicating it's undervalued in four different ways. But how reliable are these individual valuation checks? In the next section, we'll dig into the specific approaches to valuation, before ultimately sharing a smarter, more comprehensive way to size up 3SBio's worth.
Approach 1: 3SBio Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow (DCF) analysis estimates a company's intrinsic value by projecting its future free cash flows and discounting them back to today's value. This helps investors understand what a company is fundamentally worth based on its ability to generate cash.
For 3SBio, the current Free Cash Flow (FCF) is CN¥2.24 billion. Looking ahead, analysts forecast that FCF could reach CN¥4.53 billion by the end of 2029. Beyond that, projections up to 2035 show continued growth, with Simply Wall St extrapolating cash flows using modest growth rates for a total 10-year view.
All these future cash flows, estimated by both analysts and by Simply Wall St's model, are discounted back to present value using the 2 Stage Free Cash Flow to Equity method. This calculation results in an estimated intrinsic value per share of HK$52.73.
This price suggests 3SBio is trading at a 42.9% discount to its projected fair value, implying that the market may be undervaluing the company's cash-generating potential.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests 3SBio is undervalued by 42.9%. Track this in your watchlist or portfolio , or discover more undervalued stocks .
Approach 2: 3SBio Price vs Earnings
The Price-to-Earnings (PE) ratio is a go-to valuation tool for profitable companies like 3SBio because it links the company's market price directly to its earnings. This provides a snapshot of what investors are willing to pay for each dollar of profit, making it particularly useful when assessing established, earnings-generating businesses.
Typically, a "fair" PE ratio reflects the market's expectations for a company's growth, its risk profile, and what investors are paying for similar businesses in the sector. Faster-growing, lower-risk companies often command higher PE ratios, while slower-growing or riskier firms tend to trade at lower multiples.
3SBio currently trades at a PE of 27.9x. The industry average PE for Biotechs is 28.9x, while its peer group averages a loftier 52.8x. At first glance, 3SBio looks cheaper than its peers and is about in line with the broader industry. To get a clearer sense of fair value, we use Simply Wall St's proprietary Fair Ratio. This metric adjusts for the company's growth rate, size, profitability, and risk to provide a more tailored benchmark.
The Fair Ratio for 3SBio is calculated at 21.8x, which is lower than both its actual PE and the industry average. Because this metric takes into account company and industry-specific dynamics, it serves as a better barometer of underlying value than traditional raw comparisons. When comparing the Fair Ratio to the actual PE, 3SBio stock appears to be trading a bit higher than fair value, suggesting a slight premium is being attached to its shares at the moment.
Result: OVERVALUED
PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth .
Upgrade Your Decision Making: Choose your 3SBio Narrative
Earlier we mentioned that there is an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is your own story about a company, where you explain your view of its future growth, earnings, and profit margins, then translate that perspective into forecasts and a fair value estimate.
Narratives let you connect the dots between a company's story, the numbers behind it, and what you think its shares are really worth. These Narratives are easy to create and explore on Simply Wall St's Community page, where millions of investors share their perspectives and insights on companies like 3SBio.
By building or browsing Narratives, you can see exactly how different expectations line up with the current market price and get a clearer view of whether it is time to buy or sell. The best part is that they update in real time as new data and news become available, so you are always working from the latest information.
For example, some investors are bullish and see 3SBio's fair value as high as HK$60.00, while others are more cautious, estimating it closer to HK$35.80. Narratives make it easy to compare these stories and make a smarter investing decision that fits your perspective.
Do you think there's more to the story for 3SBio? Create your own Narrative to let the Community know!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 1530.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
